Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Astellas Licenses Regeneron's Velocimmune Technology | Contract Pharma

What are you searching for?

Sign in
Breaking News

Astellas Licenses Regeneron’s Velocimmune Technology

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Astellas Pharma, Inc. and Regeneron Pharmaceuticals, Inc. have entered into a non-exclusive license agreement that will allow Astellas to use Regeneron’s VelocImmune technology in its internal research programs to discover human monoclonal antibody product candidates.

Astellas will pay $20 million upfront and will make as many as five additional annual payments of $20 million. Astellas will also pay royalties on product sales derived from any antibody products discovered using VelocImmune.

“VelocImmune is the centerpiece of Regeneron’s suite of technologies for the discovery and development of fully human monoclonal antibodies,” said George D. Yancopoulos, M.D., Ph.D., president of Regeneron Research Laboratories and Regeneron’s chief scientific officer. “We are pleased that Astellas, a company with a clear strategic commitment to developing therapeutic antibodies, has selected the VelocImmune platform for its internal development programs.”

“We are excited about this license agreement with Regeneron,” said Toshinari Tamura, Ph.D., Astellas’ executive vice president and chief scientific officer. “As described in our recently announced medium term plan, Astellas is building a new technological platform for the development of antibody drugs, and VelocImmune will become an important cornerstone for our R&D capabilities.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters